Citigroup Inc Aim Immuno Tech Inc. Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Citigroup Inc holds 864 shares of AIM stock, worth $129. This represents 0.0% of its overall portfolio holdings.
Number of Shares
864Holding current value
$129% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AIM
# of Institutions
37Shares Held
8.97MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.33MShares$649,5000.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$298,3050.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$104,7400.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$69,6020.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il458KShares$68,6650.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $7.21M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...